Search

everythinglearnresearchcommunity

for

Search:↓

Male-pattern hair loss is largely influenced by genetics, with key genes identified.

Alpha-blockers are recommended first for recent CP/CPPS, while antimicrobials are not advised for long-term cases.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

Hair follicles convert androgens, affecting hair loss patterns.

Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.

The scalp has a natural speckled pattern of increased pigment around hair follicles, possibly linked to local hormone production.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.

Platelet-rich plasma injections are a promising new treatment for hair loss, showing initial positive results.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.

Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Androgenetic alopecia is mainly caused by genetic factors and increased androgen activity, leading to hair follicle miniaturization.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

5α-reductase inhibitors may lower the risk of death from bladder cancer.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.

The gene SDR5A1 is found in scalp hair of both hirsute and normal individuals, but it does not explain differences in hair growth.

Idiopathic hirsutism causes excessive hair growth in women, can be treated with medication and hair removal, but cannot be fully reversed.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Accidental findings have led to new hair treatment discoveries, like using blood pressure and diabetes medications for hair loss and unwanted hair.

3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.

The body's change of testosterone into DHT is not necessary for testosterone's muscle and sexual effects.

Gender-affirming therapy can cause skin issues like acne and hair loss in transgender adolescents, and more research is needed on its dermatological effects.

Heredity and hormones cause common hair loss, and topical minoxidil is the first recommended treatment.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.